|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 230.00 USD | -2.97% |
|
-1.63% | +25.93% |
Company Valuation: Axsome Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,424 | 3,349 | 3,766 | 4,100 | 9,207 | 11,836 | - | - |
| Change | - | 135.22% | 12.44% | 8.87% | 124.55% | 28.55% | - | - |
| Enterprise Value (EV) 1 | 1,387 | 3,243 | 3,558 | 3,966 | 9,072 | 11,725 | 11,442 | 10,865 |
| Change | - | 133.87% | 9.72% | 11.46% | 128.76% | 29.24% | -2.41% | -5.04% |
| P/E | -10.9x | -16.8x | -15.1x | -14.1x | -49.6x | -111x | 41x | 16.9x |
| PBR | 90.9x | 30.6x | 19.7x | 72.2x | 105x | 12,182x | 39.9x | 14x |
| PEG | - | -0.5x | -1x | -1x | 1.3x | 2.5x | -0x | 0x |
| Capitalization / Revenue | - | 66.9x | 13.9x | 10.6x | 14.4x | 12.1x | 7.42x | 5.25x |
| EV / Revenue | - | 64.8x | 13.1x | 10.3x | 14.2x | 12x | 7.17x | 4.82x |
| EV / EBITDA | -11.1x | -18.5x | -15.8x | -14.5x | -56.7x | -85.8x | 48.4x | 20.4x |
| EV / EBIT | -11.1x | -18x | -15.3x | -14.1x | -54.4x | -120x | 33.7x | 12.5x |
| EV / FCF | -12.8x | -27.7x | -24.4x | -30.8x | -96.6x | -194x | 30.4x | 15.1x |
| FCF Yield | -7.83% | -3.61% | -4.09% | -3.24% | -1.03% | -0.52% | 3.29% | 6.62% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.47 | -4.6 | -5.27 | -5.99 | -3.68 | -2.063 | 5.605 | 13.64 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | 50.04 | 270.6 | 385.7 | 638.5 | 979 | 1,595 | 2,255 |
| EBITDA 1 | -124.6 | -175.4 | -225 | -273.6 | -159.9 | -136.7 | 236.2 | 531.7 |
| EBIT 1 | -124.7 | -179.8 | -231.8 | -280.6 | -166.8 | -98.07 | 339.8 | 868.5 |
| Net income 1 | -130.4 | -187.1 | -239.2 | -287.2 | -183.2 | -107.4 | 310.1 | 772.6 |
| Net Debt 1 | -37.38 | -106.6 | -208.1 | -134.6 | -135.2 | -110.7 | -393.8 | -970.8 |
| Reference price 2 | 37.78 | 77.13 | 79.59 | 84.61 | 182.64 | 230.00 | 230.00 | 230.00 |
| Nbr of stocks (in thousands) | 37,692 | 43,426 | 47,320 | 48,462 | 50,413 | 51,460 | - | - |
| Announcement Date | 01/03/22 | 27/02/23 | 20/02/24 | 18/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -111.49x | 11.98x | -85.75x | -.--% | 11.84B | |
| 17.76x | 3.85x | 10.09x | 0.58% | 68.85B | |
| 25.64x | 5.3x | 15.59x | 0.61% | 52.13B | |
| 34.55x | 11.7x | 22.35x | -.--% | 43.46B | |
| -46.16x | 3.26x | 9.62x | 3.31% | 41.24B | |
| 24.47x | 3.57x | 11.94x | -.--% | 30.41B | |
| -7.13x | 10.08x | -6.19x | -.--% | 24.53B | |
| 77.55x | - | - | -.--% | 23.42B | |
| 64.32x | 6.31x | 43.41x | -.--% | 19.75B | |
| 24.47x | 5.19x | 13.62x | -.--% | 16.57B | |
| Average | 10.40x | 6.80x | 3.85x | 0.45% | 33.22B | |
| Weighted average by Cap. | 14.75x | 6.13x | 10.22x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AXSM Stock
- Valuation Axsome Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
